Engineered Probiotics for Treatment and Immunity against Viruses
AssigneeUniversity of Cincinnati
InventorsNalinikanth Kotagiri, Shindu Thomas, Nitin S. KAMBLE
Life of this patent
Estimating the term…
Abstract
The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.
Claims12
An engineered probiotic bacterium comprising a heterologous nucleic acid, wherein the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus.
Dependencies are inferred from the claim text.